A beta cell–targeting, affinity-enhanced TCR fused to a PD-1 agonist inhibits cellular immunity relevant to human type 1 diabetes.

GAINESVILLE, Fla. — Type 1 diabetes is a disease in which the body mistakenly attacks itself as the immune system destroys the pancreas’s insulin-producing…

Engineered β cells with a mutant CD155 help evade immune attack, offering a promising therapeutic approach for type 1 diabetes.

Aims/hypothesis Screening for islet autoantibodies is an effective method for identifying individuals with pre-symptomatic (stage 1 and 2) type 1 diabetes. This approach offers a valuable opportunity ...

Effector CD8+ T cells are key cellular drivers of type 1 diabetes (T1D) pathogenesis, yet questions remain regarding the molecular defects leading to altered cytotoxicity, their signature in periphera...

This study explores the inflammatory response observed in pancreata and pancreatic lymph node (pLN) samples obtained throughout the natural history of type 1 diabetes (T1D) including non-diabetic indi...

Genome sequencing results and single-cell transcriptomics continue to produce findings that challenge the idea that cancer is purely a ‘genetic disease’. This Essay delves into cancer omics data that ...